Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Common Equity (2020 - 2026)

Rani Therapeutics Holdings' Common Equity history spans 7 years, with the latest figure at $35.5 million for Q1 2026.

  • On a quarterly basis, Common Equity rose 764.48% to $35.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $35.5 million, a 764.48% increase, with the full-year FY2025 number at $41.5 million, up 1088.43% from a year prior.
  • Common Equity came in at $35.5 million for Q1 2026, down from $41.5 million in the prior quarter.
  • The five-year high for Common Equity was $110.6 million in Q1 2022, with the low at -$12.0 million in Q3 2025.
  • Historically, Common Equity has averaged $36.5 million across 5 years, with a median of $34.8 million in 2023.
  • Peak annual rise in Common Equity hit 1088.43% in 2025, while the deepest fall reached 307.32% in 2025.
  • Year by year, Common Equity stood at $74.0 million in 2022, then tumbled by 65.62% to $25.4 million in 2023, then tumbled by 86.27% to $3.5 million in 2024, then soared by 1088.43% to $41.5 million in 2025, then fell by 14.38% to $35.5 million in 2026.
  • Business Quant data shows Common Equity for RANI at $35.5 million in Q1 2026, $41.5 million in Q4 2025, and -$12.0 million in Q3 2025.